Navigation Links
Phase II Clinical Trial Results Encouraging for PA-Based Women's Health Company
Date:1/11/2011

WAYNE, Pa., Jan. 11, 2011 /PRNewswire/ -- FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder (OAB).

The Phase II FP 1097 trial demonstrated that drug can be delivered to the bladder via intra-vaginal administration successfully. The clinical trial showed a statistically significant 25 percent reduction of micturitions and a 75 percent reduction of incontinence episodes. Treatment-related adverse events were low with no serious adverse events and all subjects completing the trial. Over 50 percent of the patients on FP 1097 achieved total continence.

Based on the results, FemmePharma Global Healthcare was granted permission to proceed to a pivotal Phase III trial by the Food and Drug Administration (FDA). In addition the FDA will grant FemmePharma 505B1 filing status for FP 1097.

According to published reports, it is estimated that more than 30 million Americans (mostly women) experience OAB. IMS Healthcare estimates that the OAB prescription market in the United States exceeds $2.0 billion annually while the total worldwide market including drugs, diapers and devices exceeds $7.0 billion annually.

"The encouraging safety and efficacy results from this randomized study of FP 1097 provides a basis to advance this innovative product into Phase III clinical development," said Gerianne DiPiano, founder, President and CEO of FemmePharma Global Healthcare, Inc.


'/>"/>
SOURCE FemmePharma Global Healthcare
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
2. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
3. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
4. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
6. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
7. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
10. Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
11. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... 2013  Rahal Letterman Lanigan Racing (RLL) and StemCyte, ... cell banking and therapeutics, announced today that StemCyte has ... Stairlifts Indy car driven by James Jakes ... IZOD IndyCar 2013 season.   StemCyte, Inc. and ... awareness of umbilical cord blood banking and its educational ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... high-tech economy has yet to hit its growth spurt ... executives, Madison has what it takes to support a ... as successful as other regions? , , Accelerate Madison ... business climate through information technology, hosted a forum to ...
... Im not a big Bob Dylan fan, but lately I ... in the Wind" in which he questions mans inability ... , ,Dylans lyrics come to mind whenever the media starts ... business reengineering was all the rage. Anyone hesitating to reengineer ...
... an ancient and proud history of interstate sports rivalries ... like this past New Years Day, the rivalry generates ... and marijuana have in common? They both get smoked ... fomenting another interstate rivalry. This one is of keen ...
Cached Biology Technology:Tech Business Leaders Compare Madison to Other Regions 2Tech Business Leaders Compare Madison to Other Regions 3Tech Business Leaders Compare Madison to Other Regions 4Offshore Outsourcing: On Target or Off Base? 2Offshore Outsourcing: On Target or Off Base? 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 2For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 4
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... have determined the atomic structure of the ,binding, between ... key to treating patients with diseases such as variant ... a family of rare progressive neurodegenerative disorders, called prion ... thought that those who have developed vCJD became infected ...
... Sea the deepest point on Earth are ... according to Shahrazad Abu Ghazleh and colleagues from the ... Sea-Red Sea or Mediterranean-Dead Sea Channels therefore need a ... its former level, in order to sustainably generate electricity ...
... antiretroviral drugs in hair samples taken from HIV patients ... findings, published in the February 20 issue of ... in the hair of patients on treatment correlated strongly ... "High levels of antiretrovirals in hair correlated with ...
Cached Biology News:Antibody key to treating variant CJD, scientists find 2Is the Dead Sea dying? 2Using hair to manage HIV/AIDS and predict treatment success 2Using hair to manage HIV/AIDS and predict treatment success 3
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
... A - Fixation medium Reagent B - ... for fixing cells in suspension with Reagent ... Reagent B. This procedure gives antibodies access ... scatter characteristics of the cells intact. Specific ...
... Vision Mount is formulated for covering tissue sections and ... alcohol insoluble end products. , ... ... as Fast-Red or AEC that require an aqueous mounting medium, ...
... Retrieval Solution, High pH This pH ... retrievel prior to immunohistochemical staining procedures. It ... sections mounted on glass slides. For particular ... is especially effective. It should be noted ...
Biology Products: